Sesen Bio, Inc. (NASDAQ:SESN) recovered 123.94% of its value since hitting low of $0.66. The recent move of -19.57% drop pushed the stock to close at $1.48 when trading ended on 6/19/2019. At a recent session, the prices were hovering between $1.25 and $1.48. This company shares are 136.49% off its target price of $3.5 and the current market capitalization stands at $123.45M. The recent change has given its price a -4.13% deficit over SMA 50 and -43.08% deficit over its 52-week high. The stock witnessed -15.43% declines, 53.59% gains and 12.98% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SESN’s volatility during a week at 11.22% and during a month it has been found around 13.99%.

What Does Sesen Bio, Inc. (SESN) Do?

The company describes itself in regulatory filings as, “Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.” [Text can be found here: under company description.]

Sesen Bio, Inc. (SESN) Top Holders

Institutional investors currently hold around $34 million or 29.4% in SESN stock. Look at its top three institutional owners: Kingdon Capital Management, L.L.C. owns $9.64 million in Sesen Bio, Inc., which represents roughly 7.81% of the company’s market cap and approximately 28.36% of the institutional ownership. Similar statistics are true for the second largest owner, Trv Gp, Llc, which owns 4,841,591 shares of the stock are valued at $8.91 million. The third largest holder is Vanguard Group Inc, which currently holds $6.5 million worth of this stock and that ownership represents nearly 5.26% of its market capitalization.

Sesen Bio, Inc. 13F Filings

At the end of March reporting period, 24 institutional holders increased their position in Sesen Bio, Inc. (NASDAQ:SESN) by some 1,999,871 shares, 22 decreased positions by 13,789,515 and 14 held positions by 2,912,327. That puts total institutional holdings at 18,701,713 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 521,442 shares while 14 institutional investors sold out their entire positions totaling 12,628,762 shares.

Sesen Bio, Inc. (SESN) Analyst Guide

Several analysts have released their opinion on Sesen Bio, Inc. (NASDAQ:SESN), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].